Pfizer Oncology today announced that important data from its lung cancer
and renal cell carcinoma (RCC) portfolios will be presented at the
upcoming European Society for Medical Oncology (ESMO) Congress in
Vienna, Austria, September 28 - October 2, 2012.
"We believe that the clinical trial results to be shared at ESMO 2012
substantially enhance our knowledge of both marketed and investigational
therapies from our lung and kidney cancer portfolios," said Mace
Rothenberg, MD, senior vice president of clinical development and
medical affairs for Pfizer's Oncology Business Unit. "We are especially
pleased to be able to share, for the first time, detailed results of
PROFILE 1007, a randomized trial comparing XALKORI to standard
chemotherapy in patients with recurrent, ALK-positive non-small cell
lung cancer (NSCLC). These results, which will be presented at the
Presidential Symposium, reinforce the value of Pfizer's precision
medicine approach to drug development, and demonstrate the benefit that
targeted, efficient and science-driven cancer drug development can have
on patient outcomes."
Treating Lung Cancer Through a Targeted Approach
Data highlights relating to Pfizer's lung cancer portfolio include: